Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Zacks News
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $34.64 in the latest trading session, marking a -0.57% move from the prior day.
Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress
by Zacks Equity Research
Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.
Top Leveraged ETFs of Last Week
by Sanghamitra Saha
These leveraged ETFs won last week despite a broader market bloodbath.
5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check
by Tirthankar Chakraborty
A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
by Kinjel Shah
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
Coronavirus Drug & Vaccine: 4 Companies Leading From the Front
by Nilanjan Banerjee
The present scenario has brightened up prospects for companies working on potential drugs and vaccines to combat the pandemic.
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton
Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus
by Ekta Bagri
Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Will Moderna Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Moderna
Top Stock Trades to Beat Coronavirus Blues in April
by Tirthankar Chakraborty
The coronavirus pandemic has hit markets bad. But investors shouldn't shun stocks in April but should instead look for avenues to invest in areas under focus owing to rise in infected cases.
Moderna (MRNA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $30.48, moving +1.43% from the previous trading session.
Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine
by Zacks Equity Research
Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.
Top Ranked Momentum Stocks to Buy for March 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th
Why Is Moderna (MRNA) Up 6.8% Since Last Earnings Report?
by Zacks Equity Research
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences
3 Best U.S. Stocks Immune to Coronavirus Jitters
by Manaswita Ghosh Dutta
The pandemic may be taking a toll on markets right now but this temporary phase offers investors a window to buy equities that have a record of performing better than the broader markets.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
How To Play The W-Shaped Recovery
by Daniel Laboe
Patience is the name of the game during market downturns
Novavax Rallies as Influenza Vaccine Meets All Goals in Study
by Zacks Equity Research
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.
Top 5 Drug Stocks To Stop The Coronavirus Pandemic
by Daniel Laboe
It is only a matter of time before this virus anxiety is a thing of the past.
Coronavirus Drug Development Race to Boost These 4 Stocks
by Zacks Equity Research
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.